



# Next Steps for the Pneumococcal Vaccines Work Group

**Miwako Kobayashi, MD, MPH**

Pneumococcal Vaccines Work Group

Advisory Committee on Immunization Practices

February 24, 2022

# Policy Questions Being Considered by the Work Group

- Should PCV15 be routinely recommended for U.S. children <2 years of age **as an option for pneumococcal conjugate vaccination** according to currently recommended dosing and schedules?
- Should PCV15 be recommended for U.S. children with underlying medical conditions 2–18 years of age **as an option for pneumococcal conjugate vaccination** according to currently recommended dosing and schedules?

## Pneumococcal Conjugate Vaccine Options



# Evidence Reviewed by the Work Group


- Epidemiology of pneumococcal disease and vaccine-preventable disease burden for:
  - Invasive pneumococcal disease
  - Pneumonia
  - Acute otitis media
- Immunogenicity and safety of PCV15 in children (Phase 2/3 studies)
- GRADE and EtR
  - Public Health Problem, Benefits and Harms, Values, Equity

# Evidence to be Reviewed by the Work Group

- Epidemiology of pneumococcal disease and vaccine-preventable disease burden for:
  - Invasive pneumococcal disease
  - Pneumonia
  - Acute otitis media
- Immunogenicity and safety of PCV15 in children (Phase 2/3 studies)
- **GRADE and EtR**
  - Public Health Problem, Benefits and Harms, Values, Equity
  - Resource Use (Cost-effective analysis), Acceptability, Feasibility

## Proposed Timeline of ACIP Presentations (Tentative)

Feb 2022  
ACIP



June '22  
ACIP

Presentation on:

- Pediatric Pneumococcal disease epi
- Phase 2/3 PCV15 studies in children
- EtR (part 1)/GRADE

Presentation on:

- Cost-effectiveness analysis
- EtR (part 2)

Vote (if product licensed for use)

# Questions for the Committee

- Does the Committee agree with the policy questions being considered by the Work Group?
- Are there additional data the Committee would like to see before deciding on policy options for a vote?

# Thank you!

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

